Medulloblastoma (MB) is the most common malignant brain tumor in children. It is known that overexpression and/or amplification of the MYC oncogene is associated with poor clinical outcome, but the molecular mechanisms and the MYC downstream effectors in MB remain still elusive. Besides contributing to elucidate how progression of MB takes place, most importantly, the identification of novel MYC-target genes will suggest novel candidates for targeted therapy in MB. A group of 209 MYC-responsive genes was obtained from a complementary DNA microarray analysis of a MB-derived cell line, following MYC overexpression and silencing. Among the MYC-responsive genes, we identified the members of the bone morphogenetic protein (BMP) signaling pathway, which have a crucial role during the development of the cerebellum. In particular, the gene BMP7 was identified as a direct target of MYC. A positive correlation between MYC and BMP7 expression was documented by analyzing two distinct sets of primary MB samples. Functional studies in vitro using a small-molecule inhibitor of the BMP/SMAD signaling pathway reproduced the effect of the small interfering RNA-mediated silencing of BMP7. Both approaches led to a block of proliferation in a panel of MB cells and to inhibition of SMAD phosphorylation. Altogether, our findings indicate that high MYC levels drive BMP7 overexpression, promoting cell survival in MB cells. This observation suggests the potential relevance of targeting the BMP/SMAD pathway as a novel therapeutic approach for the treatment of childhood MB.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Lisa: inferring transcriptional regulators through integrative modeling of public chromatin accessibility and ChIP-seq data
Genome Biology Open Access 07 February 2020
Journal of Translational Medicine Open Access 03 February 2020
Acta Neuropathologica Communications Open Access 07 April 2014
Subscribe to Journal
Get full journal access for 1 year
only $2.38 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Adhikary S, Eilers M . (2005). Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 6: 635–645.
Alder J, Lee KJ, Jessell TM, Hatten ME . (1999). Generation of cerebellar granule neurons in vivo by transplantation of BMP-treated neural progenitor cells. Nat Neurosci 2: 535–540.
Aldosari N, Bigner SH, Burger PC, Becker L, Kepner JL, Friedman HS et al. (2002). MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med 126: 540–544.
Anderson GJ, Darshan D . (2008). Small-molecule dissection of BMP signaling. Nat Chem Biol 4: 15–16.
Arihiro K, Inai K . (2001). Expression of CD31, Met/hepatocyte growth factor receptor and bone morphogenetic protein in bone metastasis of osteosarcoma. Pathol Int 51: 100–106.
Balemans W, Van Hul W . (2002). Extracellular regulation of BMP signaling in vertebrates: a cocktail of modulators. Dev Biol 250: 231–250.
Behesti H, Marino S . (2009). Cerebellar granule cells: insights into proliferation, differentiation, and role in medulloblastoma pathogenesis. Int J Biochem Cell Biol 41: 435–445.
Blanco Calvo M, Bolos Fernandez V, Medina Villaamil V, Aparicio Gallego G, Diaz Prado S, Grande Pulido E . (2009). Biology of BMP signalling and cancer. Clin Transl Oncol 11: 126–137.
Buijs JT, Henriquez NV, van Overveld PG, van der Horst G, Que I, Schwaninger R et al. (2007a). Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res 67: 8742–8751.
Buijs JT, Petersen M, van der Horst G, van der Pluijm G . (2010). Bone morphogenetic proteins and its receptors; therapeutic targets in cancer progression and bone metastasis? Curr Pharm Des 16: 1291–1300.
Buijs JT, Rentsch CA, van der Horst G, van Overveld PG, Wetterwald A, Schwaninger R et al. (2007b). BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol 171: 1047–1057.
Chen JK, Taipale J, Cooper MK, Beachy PA . (2002). Inhibition of Hedgehog signaling by direct binding of cyclopamine to smoothened. Genes Dev 16: 2743–2748.
Chizhikov VV, Lindgren AG, Currle DS, Rose MF, Monuki ES, Millen KJ . (2006). The roof plate regulates cerebellar cell-type specification and proliferation. Development 133: 2793–2804.
Crawford JR, MacDonald TJ, Packer RJ . (2007). Medulloblastoma in childhood: new biological advances. Lancet Neurol 6: 1073–1085.
Dai J, Hall CL, Escara-Wilke J, Mizokami A, Keller JM, Keller ET . (2008). Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms. Cancer Res 68: 5785–5794.
Derynck R, Akhurst RJ, Balmain A . (2001). TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29: 117–129.
Dziegielewska KM, Ek J, Habgood MD, Saunders NR . (2001). Development of the choroid plexus. Microsc Res Tech 52: 5–20.
Eberhart CG, Kepner JL, Goldthwaite PT, Kun LE, Duffner PK, Friedman HS et al. (2002). Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer 94: 552–560.
Edgar R, Domrachev M, Lash AE . (2002). Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207–210.
Engelhard HH, Corsten LA . (2005). Leptomeningeal metastasis of primary central nervous system (CNS) neoplasms. Cancer Treat Res 125: 71–85.
Feeley BT, Gamradt SC, Hsu WK, Liu N, Krenek L, Robbins P et al. (2005). Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J Bone Miner Res 20: 2189–2199.
Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J et al. (2003). Genomic targets of the human c-Myc protein. Genes Dev 17: 1115–1129.
Filmus J, Capurro M, Rast J . (2008). Glypicans. Genome Biol 9: 224.
Gilbertson RJ, Ellison DW . (2008). The origins of medulloblastoma subtypes. Annu Rev Pathol 3: 341–365.
Grandori C, Cowley SM, James LP, Eisenman RN . (2000). The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 16: 653–699.
Grimmer MR, Weiss WA . (2008). BMPs oppose Math1 in cerebellar development and in medulloblastoma. Genes Dev 22: 693–699.
Grisaru S, Cano-Gauci D, Tee J, Filmus J, Rosenblum ND . (2001). Glypican-3 modulates BMP- and FGF-mediated effects during renal branching morphogenesis. Dev Biol 231: 31–46.
Grotzer MA, Castelletti D, Fiaschetti G, Shalaby T, Arcaro A . (2009). Targeting Myc in pediatric malignancies of the central and peripheral nervous system. Curr Cancer Drug Targets 9: 176–188.
Guessous F, Li Y, Abounader R . (2008). Signaling pathways in medulloblastoma. J Cell Physiol 217: 577–583.
Guhaniyogi J, Brewer G . (2001). Regulation of mRNA stability in mammalian cells. Gene 265: 11–23.
Guo X, Wang XF . (2009). Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res 19: 71–88.
Gurney JG, Kadan-Lottick N . (2001). Brain and other central nervous system tumors: rates, trends, and epidemiology. Curr Opin Oncol 13: 160–166.
Herms J, Neidt I, Luscher B, Sommer A, Schurmann P, Schroder T et al. (2000). C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer 89: 395–402.
Iantosca MR, McPherson CE, Ho SY, Maxwell GD . (1999). Bone morphogenetic proteins-2 and -4 attenuate apoptosis in a cerebellar primitive neuroectodermal tumor cell line. J Neurosci Res 56: 248–258.
Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP . (2003). Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.
Krizhanovsky V, Ben-Arie N . (2006). A novel role for the choroid plexus in BMP-mediated inhibition of differentiation of cerebellar neural progenitors. Mech Dev 123: 67–75.
Kunz F, Shalaby T, Lang D, von Buren A, Hainfellner JA, Slavc I et al. (2006). Quantitative mRNA expression analysis of neurotrophin-receptor TrkC and oncogene c-MYC from formalin-fixed, paraffin-embedded primitive neuroectodermal tumor samples. Neuropathology 26: 393–399.
Lamont JM, McManamy CS, Pearson AD, Clifford SC, Ellison DW . (2004). Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 10: 5482–5493.
Langenfeld EM, Calvano SE, Abou-Nukta F, Lowry SF, Amenta P, Langenfeld J . (2003). The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis 24: 1445–1454.
Littlewood TD, Evan GI . (1990). The role of myc oncogenes in cell growth and differentiation. Adv Dent Res 4: 69–79.
Luo J, Chen J, Deng ZL, Luo X, Song WX, Sharff KA et al. (2007). Wnt signaling and human diseases: what are the therapeutic implications? Lab Invest 87: 97–103.
Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D et al. (2010). miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12: 247–256.
Marino S . (2005). Medulloblastoma: developmental mechanisms out of control. Trends Mol Med 11: 17–22.
Miyazaki H, Watabe T, Kitamura T, Miyazono K . (2004). BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells. Oncogene 23: 9326–9335.
Miyazono K . (1999). Signal transduction by bone morphogenetic protein receptors: functional roles of Smad proteins. Bone 25: 91–93.
Miyazono K, Kamiya Y, Morikawa M . (2010). Bone morphogenetic protein receptors and signal transduction. J Biochem 147: 35–51.
Miyazono K, Maeda S, Imamura T . (2005). BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev 16: 251–263.
Mulhern RK, Palmer SL, Merchant TE, Wallace D, Kocak M, Brouwers P et al. (2005). Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol 23: 5511–5519.
Neben K, Korshunov A, Benner A, Wrobel G, Hahn M, Kokocinski F et al. (2004). Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res 64: 3103–3111.
Piccirillo SG, Vescovi AL . (2006). Bone morphogenetic proteins regulate tumorigenicity in human glioblastoma stem cells. Ernst Schering Found Symp Proc 5: 59–81.
Polkinghorn WR, Tarbell NJ . (2007). Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol 4: 295–304.
Raida M, Clement JH, Ameri K, Han C, Leek RD, Harris AL . (2005). Expression of bone morphogenetic protein 2 in breast cancer cells inhibits hypoxic cell death. Int J Oncol 26: 1465–1470.
Redzic ZB, Segal MB . (2004). The structure of the choroid plexus and the physiology of the choroid plexus epithelium. Adv Drug Deliv Rev 56: 1695–1716.
Romer J, Curran T . (2005). Targeting medulloblastoma: small-molecule inhibitors of the Sonic Hedgehog pathway as potential cancer therapeutics. Cancer Res 65: 4975–4978.
Rossi A, Caracciolo V, Russo G, Reiss K, Giordano A . (2008). Medulloblastoma: from molecular pathology to therapy. Clin Cancer Res 14: 971–976.
Sieber C, Kopf J, Hiepen C, Knaus P . (2009). Recent advances in BMP receptor signaling. Cytokine Growth Factor Rev 20: 343–355.
Stearns D, Chaudhry A, Abel TW, Burger PC, Dang CV, Eberhart CG . (2006). c-Myc overexpression causes anaplasia in medulloblastoma. Cancer Res 66: 673–681.
Sutter R, Shakhova O, Bhagat H, Behesti H, Sutter C, Penkar S et al. (2010). Cerebellar stem cells act as medulloblastoma-initiating cells in a mouse model and a neural stem cell signature characterizes a subset of human medulloblastomas. Oncogene 29: 1845–1856.
Thawani JP, Wang AC, Than KD, Lin CY, La Marca F, Park P . (2010). Bone morphogenetic proteins and cancer: review of the literature. Neurosurgery 66: 233–246; discussion 246.
Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC et al. (2006). Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 24: 1924–1931.
Vita M, Henriksson M . (2006). The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 16: 318–330.
von Bueren AO, Shalaby T, Rajtarova J, Stearns D, Eberhart CG, Helson L et al. (2007). Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells. BMC Cancer 7: 19.
Walsh DW, Godson C, Brazil DP, Martin F . (2010). Extracellular BMP-antagonist regulation in development and disease: tied up in knots. Trends Cell Biol 20: 244–256.
Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, Lingner J et al. (1999). Direct activation of TERT transcription by c-MYC. Nat Genet 21: 220–224.
Yabe T, Samuels I, Schwartz JP . (2002). Bone morphogenetic proteins BMP-6 and BMP-7 have differential effects on survival and neurite outgrowth of cerebellar granule cell neurons. J Neurosci Res 68: 161–168.
Yan W, Chen X . (2007). Targeted repression of bone morphogenetic protein 7, a novel target of the p53 family, triggers proliferative defect in p53-deficient breast cancer cells. Cancer Res 67: 9117–9124.
Yanagita M . (2005). BMP antagonists: their roles in development and involvement in pathophysiology. Cytokine Growth Factor Rev 16: 309–317.
Yanagita M . (2009). BMP modulators regulate the function of BMP during body patterning and disease progression. Biofactors 35: 113–119.
Ye L, Bokobza SM, Jiang WG . (2009). Bone morphogenetic proteins in development and progression of breast cancer and therapeutic potential (review). Int J Mol Med 24: 591–597.
Ye L, Lewis-Russell JM, Davies G, Sanders AJ, Kynaston H, Jiang WG . (2007). Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells. Int J Oncol 30: 521–529.
Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Hoyng SA et al. (2008). Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol 4: 33–41.
Zeller KI, Zhao X, Lee CW, Chiu KP, Yao F, Yustein JT et al. (2006). Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci USA 103: 17834–17839.
Zhao H, Ayrault O, Zindy F, Kim JH, Roussel MF . (2008). Post-transcriptional down-regulation of Atoh1/Math1 by bone morphogenic proteins suppresses medulloblastoma development. Genes Dev 22: 722–727.
Giulio Fiaschetti and Deborah Castelletti were supported by the European Community FP6, project STREP (EET-pipeline, number: 037260).
The authors declare no conflict of interest.
Supplementary Information accompanies the paper on the Oncogene website
The original online version of this article was revised: Following publication of this article, the authors noted Figure 1b incorrectly reported beta-tubulin as the control used for the Western blot analysis when beta-actin was used. In addition, in this figure, the control bands of DAOY cells M2.1 and M14 were inadvertently swapped. The authors apologise for the inconvenience caused and confirm this does not have any impact on the interpretation of the results. The original article has been corrected.
About this article
Cite this article
Fiaschetti, G., Castelletti, D., Zoller, S. et al. Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma. Oncogene 30, 2823–2835 (2011). https://doi.org/10.1038/onc.2011.10
- brain tumor
- pediatric cancer
This article is cited by
Journal of Translational Medicine (2020)
Lisa: inferring transcriptional regulators through integrative modeling of public chromatin accessibility and ChIP-seq data
Genome Biology (2020)
Acta Neuropathologica (2019)
Acta Neuropathologica (2017)
Acta Neuropathologica Communications (2014)